FDA con­cerns at con­trac­tor Catal­ent site spurred on short­ages of No­vo Nordisk's semaglu­tide — re­port

Just be­fore the start of the new year, No­vo Nordisk re­vealed its sup­ply of obe­si­ty med We­govy was low and that it would not be able to meet de­mand in the US un­til the sec­ond half of 2022.

Thanks to a Form 483 from the FDA, we now know that is­sues at Catal­ent’s flag­ship sy­ringe fill­ing site in Brus­sels, Bel­gium, was the rea­son for the de­lay, Bio­Process In­ter­na­tion­al re­port­ed.

The site is 265,000 square feet and has been hand­ed 12 483s in nine FDA vis­its, a source told Bio­Process, though it is be­lieved that this is the first that has halt­ed pro­duc­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER